



ASX / MEDIA RELEASE

Melbourne, Australia, Tuesday 1st December 2009

**The University Medical Center in Freiburg,
Germany chooses Compumedics' new LTM EEG
system, Neuvo®, ahead of all major
international competitors**

Leading Australia-based medical-devices company, Compumedics Limited (ASX: CMP) is pleased to announce that the internationally renowned University Medical Center (UMC) in Freiburg, Germany has chosen Compumedics' recently released, long-term EEG monitoring (LTM) system, Neuvo® to equip its world class epileptology (epilepsy) center. The sale represents approximately \$600k (€350k) in new incremental revenues to Compumedics and is a major milestone as the Company begins to roll-out its Neuvo® LTM system to the approximately USD1.0bn per annum global neurological monitoring market.

UMC Freiburg is the teaching hospital within the University of Freiburg, which is considered to be one of Europe's most prestigious universities, attracting students world-wide. It is recognised as the home of some of the greatest minds, including affiliation with 19 Nobel laureates and 13 academics who have been honored, while working at the University of Freiburg, with Germany's highest research prize, the Gottfried Wilhelm Leibnitz Prize.

UMC Freiburg has an annual budget in the order of €500 million to service 1,600 beds, 55,000 in-patients and 357,000 out-patients each year. UMC Freiburg employs about 7,750 medical staff.

The winning of the UMC Freiburg Epileptology centre tender is a major milestone for the Compumedics' Neuvo® LTM system, and

For personal use only

incorporates the industry gold-standard Compumedics®/Neuroscan® Curry® source-reconstruction software and the Compumedics®/Nexus clinical enterprise system.

The decision by UMC Freiburg to choose Compumedics' new Neuvo® LTM system over all major international competitors was primarily driven by Compumedics':

- ability to deliver premium quality, high-definition amplifiers
- fully integrated laboratory management tool, Profusion™ Nexus™, a high productivity software package for managing all aspects of the day-to-day running of the laboratory plus its electronic data storage and retrieval requirements;
- advanced state-of-the-art digital video and audio recording capabilities; and
- integration with Compumedics®/Neuroscan® gold-standard Curry® source-reconstruction software.

This installation marks the start of Compumedics' new LTM neurology Neuvo® global roll-out, where the market opportunity in the US is in excess of \$300m per annum and in Europe is more than \$250m per annum. The Neuvo® LTM incorporates unsurpassed quality recording, comprehensive analysis and integrated data management and workflow, which are hallmarks of neurology clinical and research excellence.

Compumedics is now in the process of strengthening its Neuvo® LTM system distribution channels across Europe, which provides an exciting opportunity for new Compumedics distributors who are looking for product differentiation and best-of-class LTM neurology system offerings. Compumedics has received a number of high caliber applications for Neuvo® LTM distribution, and the Company will continue to update the market as these new contracts and associated global LTM neurology incremental revenue strategies progress.

For Further information:

Mr David Burton
Executive Chairman, CEO
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Mr David Lawson
Chief Financial Officer
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

For personal use only

Investor Relations & Media Enquires:

Mr Rod North
Managing Director
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: +61 (0) 408 670 706

About Compumedics

Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. **In 1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. **In 1998** Compumedics was awarded the overall Australian Exporter of the Year. In **2000** Compumedics was listed on the Australian Stock Exchange. **In 2002**, Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. **In 2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. **In 2004**, Compumedics acquired German-based DWL Elektronische GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. **In 2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. **In 2007**, Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. **In 2008** the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from \$9 million (1999) to \$38 million (2009). **In 2009** Compumedics was awarded a design award for its Grael™ PSG/EEG premium laboratory based product. www.compumedics.com